The University of California, Davis (UC Davis) is requesting continued support for the Clinical and Translational Science Center (CTSC). Since its initiation, the UC Davis CTSC has been firmly established as a major local, regional, and national leader in transforming the clinical and translational research enterprise and has received enthusiastic support from throughout UC Davis. The CTSC has created an extensive community of partners, ranging from the UC Davis Health System, colleges and schools to local community partners, regional partners including the University of Nevada and national partners, and other CTSA sites. The CTSC has fostered a cadre of successful trainees that are well prepared for a career trajectory in clinical and translational research, built an extensive infrastructure to support trainees, investigators, and community partners, and emerged as a major contributor to national CTSA goals. At the end of the initial funding period, the UC Davis CTSC is an organization that is: (1) responsive and familiar to investigators;(2) flexible;(3) versatile;(4) well-linked to university leadership, to participating academic units, and to the community;and (5) actively reducing barriers and facilitating translation of research gains into medical practice. The key features of our program are: education programs focused on """"""""team science"""""""";flexible infrastructure;extensive collaborations across UC Davis;and engagement of local, regional, and national partners. The CTSC has played major leadership roles in establishing the national CTSA Consortium, and has been a leader or collaborator on 15 CTSA supplemental awards. In the next grant period, the CTSC will focus on 3 goals firmly anchored in our institutional fabric, the community, and the CTSA Consortium: (1) Completion of a comprehensive service and resource toolset for the research community;(2) Education and training of a well prepared workforce of trainees, staff, and investigators;and (3) Ensuring translational research is advanced to improve human health across the lifespan. To realize these goals, the CTSC will remain under the continued leadership of Lars Berglund, MD, PhD, supported by a cadre of directors and associate directors overseeing individual CTSC programs, and guided by a comprehensive committee structure designed to firmly anchor the CTSC with institutional leadership, faculty, trainees, the community, and the national CTSA Consortium.
The UC Davis CTSC has established a strong training and infrastructure resource to support and promote health research. Through the CTSC, research findings relevant to health and disease are made available to health professionals and community members. In addition, the UC Davis CTSC is part of a national network to ensure a broad-based information exchange between scientists, health professionals, and community members.
|Henry, Stephen G; Romano, Patrick S; Yarborough, Mark (2016) Building Trust Between Institutional Review Boards and Researchers. J Gen Intern Med 31:987-9|
|Humphries, Misty D; Brunson, Ann; Li, Chin-Shang et al. (2016) Amputation trends for patients with lower extremity ulcers due to diabetes and peripheral artery disease using statewide data. J Vasc Surg 64:1747-1755.e3|
|Oskarsson, Bjorn; Joyce, Nanette C; De Bie, Evan et al. (2016) Upper extremity 3-dimensional reachable workspace assessment in amyotrophic lateral sclerosis by Kinect sensor. Muscle Nerve 53:234-41|
|Mamalis, Andrew; Koo, Eugene; Garcha, Manveer et al. (2016) High fluence light emitting diode-generated red light modulates characteristics associated with skin fibrosis. J Biophotonics 9:1167-1179|
|Mamalis, Andrew; Siegel, Daniel; Jagdeo, Jared (2016) Visible Red Light Emitting Diode Photobiomodulation for Skin Fibrosis: Key Molecular Pathways. Curr Dermatol Rep 5:121-128|
|Nishijima, Daniel K; Gaona, Samuel; Waechter, Trent et al. (2016) Do EMS Providers Accurately Ascertain Anticoagulant and Antiplatelet Use in Older Adults with Head Trauma? Prehosp Emerg Care :1-7|
|Henry, Stephen G (2016) Evaluating the Risks of Opioid Use for Chronic Pain: Moving Beyond Overdose. J Gen Intern Med 31:453-4|
|Ho, Derek; Kraeva, Ekaterina; Wun, Ted et al. (2016) A single-blind, dose escalation, phase I study of high-fluence light-emitting diode-red light (LED-RL) on human skin: study protocol for a randomized controlled trial. Trials 17:385|
|Oskarsson, BjÃ¶rn; Rocke, David M; Dengel, Karsten et al. (2016) Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology 86:1159-63|
|Nishijima, Daniel K; Monuteaux, Michael C; Faraoni, David et al. (2016) Tranexamic Acid Use in United States Children's Hospitals. J Emerg Med 50:868-874.e1|
Showing the most recent 10 out of 45 publications